USA TODAY - FDA: Strattera may carry risk of suicide
The attention-deficit drug Strattera may prompt children and teens to consider or attempt suicide, the Food and Drug Administration warned Thursday.
The FDA ordered Strattera’s maker, Eli Lilly & Co., to add a “black box” warning, the FDA’s strongest alert, to the drug’s label. It advises doctors and patients to be on guard for mood changes or suicidal thinking.
Doctors last year wrote about 5.9 million prescriptions for Strattera, compared with roughly 7.7 million each for its leading rivals, Adderall and Concerta, according to IMS Health, a firm that tracks drug trends.
Children with the attention disorder are impulsive, easily distracted and unable to concentrate at the same level as their peers.
Related Results
Finding What Works
Holmes Herbs, Inc.: Qualia Completes Research Contract for Eli Lilly
New advice on use of strattera (atomoxetine).
Study Shows Treatment With ADHD Medication May Be As Effective in African Ame…
British agency cites new risks with atomoxetine.(News)
The warning follows an analysis of 12 Strattera studies. The analysis suggests the drug appears to promote thoughts of suicide, the FDA said. Of 1,357 children and teens who took the drug, five …
Read the full article with a Free Trial at MyWire.
